Gefitinib-induced Acute Fatal Respiratory Failure in a Woman who Never Smoked and had Adenocarinoma of the Lung with EGFR Mutation |
Kim, Sang-Gu
(Department of Internal Medicine, College of Medicine, Inha University)
Ryu, Jeong-Seon (Department of Internal Medicine, College of Medicine, Inha University) Han, Jee-Young (Department of Internal Medicine, College of Medicine, Inha University) Kim, Hyun-Jung (Department of Internal Medicine, College of Medicine, Inha University) Cho, Jae-Hwa (Department of Internal Medicine, College of Medicine, Inha University) Kwak, Seung-Min (Department of Internal Medicine, College of Medicine, Inha University) Lee, Hong-Lyeol (Department of Internal Medicine, College of Medicine, Inha University) |
1 | Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-smallcell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56 DOI ScienceOn |
2 | Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin- induced lung fibrosis in mice. Am J Respir Crit Care Med 2006;174:550-6 DOI ScienceOn |
3 | Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs 2003;14:665-8 DOI ScienceOn |
4 | Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005;23:2423-4 DOI ScienceOn |
5 | Okamoto I, Fujii K, Matsumoto M, Terasaki Y, Kihara N, Kohrogi H, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003;40:339-42 DOI ScienceOn |
6 | Seto T, Seki N, Uematsu K, Tanigaki T, Shioya S, Koboyashi T, et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology 2006;11:113-6 DOI ScienceOn |
7 | Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9 DOI ScienceOn |
8 | Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-8 DOI |
9 | Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104 DOI ScienceOn |
10 | Fujiwara Y, Kiura K, Toyooka S, Takigawa N, Tokumo M, Hotta K, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2006;52:99-103 DOI ScienceOn |
11 | Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003;63:5054-9 |
12 | Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003;22:179-81 DOI |
13 | Sumpter K, Harper-Wynne C, O'Brien M, Congleton J. Severe acute interstitial pnuemonia and gefitinib. Lung Cancer 2004;43:367-8 DOI ScienceOn |
14 | Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y. Acute gefitinib-induced pneumonitis. Int J Clin Oncol 2004;9:406-9 DOI ScienceOn |
15 | Inomata S, Takahashi H, Nagata M, Yamada G, Shiratori M, Tanaka H, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004;15:461-7 DOI ScienceOn |